Inhibrx INBRX-106 nears doubles response in Phase 2 HNSCC
Inhibrx reports INBRX-106 nearly doubles response rate and interim median PFS of 9.6 months in its Phase 2 HNSCC study.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.